Status:
RECRUITING
Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Rectal Cancer Stage I
Eligibility:
All Genders
18+ years
Brief Summary
BACKGROUND: Rectal cancer is the sixth most common neoplasm in Spain. In the early stages (pT1-N0), the treatment of choice is transanal endoscopic microsurgery. Treatment may be expanded to radical s...
Detailed Description
HYPOTHESIS: Taulí-T1 classification will have greater clinical utility to classify the stage pT1 rectal adenocarcinomas compared with conventional classifications. OBJECTIVE: The main objective of th...
Eligibility Criteria
Inclusion
- Rectal adenocarcinoma.
- Histopathologically diagnosed with stage pT1.
- Patients treated with transanal endoscopic surgery technique (TME, TEO or TAMIS).
- Patients who have received prior neoadjuvant treatment (radiotherapy and/or chemotherapy).
- Over 18 years.
Exclusion
- Patients treated with other surgical techniques other than transanal endoscopic surgery.
- Tumors other than adenocarcinoma.
- Locations other than rectum.
Key Trial Info
Start Date :
October 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 5 2026
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT06218108
Start Date
October 2 2023
End Date
January 5 2026
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Parc Tauli de Sabadell
Sabadell, Barcelona, Spain, 08208